

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
018733/0997SERIAL NO. 09/676,783  
08/893,749

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

William J. McBRIDE et al.

FILING DATE

10/02/2000 *sk*

GROUP ART UNIT

Unassigned 1639

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>tdw</i>	A1	4,822,890	4/89	Bolin	548	344	
	A2	5,225,180	7/93	Dean et al.	424	1.1	
	A3	4,564,472	1/86	Ueda et al.	260	113	
	A4	5,227,474	7/93	Johnson et al.	534	558	
	A5	5,449,761	9/95	Belinka, Jr, et al.	534	10	
	A6	5,753,206	05/98	McBride et al.	424	1.69	
<i>↓</i>	A7	5,080,884	01/92	McBride et al.	424	1.1	

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
<i>tdw</i>	A8	96/40756	12/96	WIPO				
	A9	91/01144	2/91	WIPO				
	A10	93/21962	11/93	WIPO				
	A11	93/25244	12/93	WIPO				
	A12	94/23758	10/94	WIPO				
	A13	94/26294	11/94	WIPO				
	A14	94/28942	12/94	WIPO				
<i>↓</i>	A15	0 536 741	4/93	Europe				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>tdw</i>	A16	Virgolini et al., "Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors" <u>The New England Journal of Medicine</u> pp. 1116-1121 (1994)
	A17	Virgolini et al., "Vasoactive Intestinal Peptide Receptor Scintigraphy" <u>The Journal of Nuclear Medicine</u> 36:1732-1739 (1995)
	A18	Lister-Jamcs et al., "Radiopharmaceutical Chemistry: Protein, Peptides, Antibodies I" <u>No. 370</u> 36:91P, (1995)
	A19	Pearson et al., "Somatostatin Receptor-Binding Peptides Labeled with Technetium-99m: Chemistry and Initial Biological Studies" <u>J. Med. Chem.</u> 39:1361-1371 (1996)
	A20	Krenning et al., "Somatostatin Receptor Scintigraphy with Indium-111-DTPA-D-Phe-1-Octreotide in Man: Metabolism, Dosimetry and Comparison with Iodine-123-Tyr-3-Octreotide" <u>The Journal of Nuclear Medicine</u> 33:652-658 (1992)
<i>↓</i>		

EXAMINER

*T. Wang*

DATE CONSIDERED

1/23/06

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/099		SERIAL NO. <i>09/6761783</i> <del>08/893,749</del>	
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)				APPLICANT William J. McBRIDE et al.			
				FILING DATE 10/02/2000		GROUP ART UNIT <del>Unassigned</del> <i>1639</i>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>T.D.W.</i>	A21	Wraight et al., "The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of melanoma" <u>The British Journal of Radiology</u> 65:112-118 (1992)					
	A22	Reubi, "In Vitro Identification of Vasoactive Intestinal Peptide Receptors in Human Tumors: Implications for Tumor Imaging" <u>The Journal of Nuclear Medicine</u> 36:1846-1853 (1995)					
	A23	Maina et al., "Synthesis, Radiochemical and Biological Evaluation of <sup>99m</sup> Tc[N4(D)Phe <sup>1</sup> ]-Octreotide, a New Octreotide Derivative with High Affinity for Somatostatin Receptor" <u>The Journal of Nuclear Biology and Medicine</u> pp.452 (1994)					
	A24	Bajusz et al., "Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone" Proc. Natl. Acad. Sci. USA 86:6313-6317 (1989)					
	A25	Felix et al., "Synthesis, biological activity and conformational analysis of cyclic GRF analogs" J. Peptide Protein Res. 32:441-454 (1988)					
	A26	Edwards et al., "Generally Applicable, Convenient Solid-Phase Synthesis and Receptor Affinities of Octreotide Analogs" <u>J. Med. Chem.</u> 37:3749-3757 (1994)					
	A27	Biestock et al., "Conformational Analysis of a Highly Potent Dicyclic Gonadotropin-Releasing Hormone Antagonist by Nuclear Magnetic Resonance and Molecular Dynamics" <u>American Chemical Society</u> pp.3265-3273 (1993)					
	A28	Barbacci et al., "The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding" The Journal of Biological Chemistry 270:9585-9589 (1995)					
	A29	Haskell-Luevano et al., "Characterizations of the Unusual Dissociation Properties of Melanotropin Peptides from the Melanocortin Receptor, hMC1R" <u>J. Med. Chem.</u> 39:432-435 (1996)					
	A30	Al-Obeidi et al., "Design of a New Class of Superpotent Cyclic $\alpha$ -Melanotropins Based on Quenched Dynamic Simulations" <u>J. AM. Chem. Soc.</u> 111:3413-3416 (1989)					
	A31	O'Donnell et al., "Ro 25-1553: A Novel, Long-Acting Vasoactive Intestinal Peptide Agonist. Part I: In Vitro and In Vivo Bronchodilator Studies" The Journal of Pharmacology and Experimental Therapeutics 270:1282-1294 (1994)					
<i>✓</i>	A32	Virgolini et al., "Cross-Competition between Vasoactive Intestinal Peptide and Somatostatin for Binding to Tumor Cell Membrane Receptors" <u>Cancer Research</u> pp.690-700 (1994)					
EXAMINER <i>T. D. 7</i>				DATE CONSIDERED <i>1/27/06</i>			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							